Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
EAGLE PHARMACEUTICALS, INC. (EGRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Second Quarter 2023 Results · Total revenue for Q2 2023 was $64.6 million · Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income 1 was $1.18 per basic and diluted share · Q2 2023 net income was $5.2 million · Q2 2023 adjusted non-GAAP EBITDA 1 was $20.7 million · Gross margin was 74% for the first half of 2023, up from 73% for the first half of 2022 · Adjusted non-GAAP gross margin 1 was 83% for the first half of 2023, up from 74% for the first half of 2022 · Gross profit in its oncology business was $41.9 million in the second quarter of 2023 compared with $38.7 million in the prior year period, representing gross margin of 80% and 72%, respectively · Adjusted non-GAA..."
05/09/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports First Quarter 2023 Results · Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 · Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income 1 was $1.27 per basic and $1.26 per diluted share · Q1 2023 adjusted non-GAAP EBITDA of $22.3 million · Q1 2023 net sales of PEMFEXY totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial pemetrexed market for the second quarter of 2023 to date 2 · BENDEKA ®3 and BELRAPZO ®4 - both ready-to-dilute products — combined maintained approximately 89% share of the bendamustine U.S. market for the first quarter of 2023 compared to approximately 90% historically 5 · Company reaffirms full yea..."
03/13/2023 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results · Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share 1 · Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 · FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share 1 · FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 · FY 2022 net sales of PEMFEXY ® totaled $67.5 million, and were $12.1 million in Q4 2022, representing a 6% U.S. market share in community oncology at the end of Q4 2022; already captured a 10% share through February 2023; antici..."
11/09/2022 8-K/A Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Third Quarter 2022 Results · Q3 2022 net loss was $ per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share 1 · Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021 · Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted share · Nine-month 2022 adjusted non-GAAP earnings per diluted share 1 more than doubled to $6.69 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company’ s history · Nine-month 2022 revenue of $255.9 million exceeds full year 2021 revenue of $171.5 million · Nine-month 2022 net sales of vasopressin and PEMFEXY combined totaled $114.9 million · BEN..."
08/09/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Third Quarter 2021 Results ·       Q3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share ·       Expect to receive approval for Abbreviated New Drug Application for vasopressin; December 15, 2021 GDUFA date ·       Received favorable district court decision that Eagle’ s proposed vasopressin product does not infringe any of the patents Par asserted against Eagle ·       Entered into worldwide licensing agreement for CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 devel..."
05/10/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "Eagle Pharmaceuticals Reports Third Quarter 2020 Results -- Q3 2020 net income was $0.52 per basic and $0.51 per diluted share and adjusted non-GAAP net income was $1.19 per basic and $1.17 per diluted share --",
"Eagle Pharmaceuticals Strengthens Management Team to Prepare for Future Growth"
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results — Q2 2019 net income of $0.49 per basic and $0.48 per diluted share and adjusted non-GAAP net income of $0.86 per basic and $0.84 per diluted share — — Announced clinical development plan for its innovative fulvestrant program intended to deliver maximum estrogen receptor inhibition in patients with estrogen receptor -positive breast cancer — — Pipeline programs advancing on track; Eagle reiterating R&D expense guidance"
05/07/2019 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results — Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of $1.05 per basic and $1.01 per diluted share"
02/28/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results"
08/07/2018 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Second Quarter 2018 Results"
05/10/2018 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results"
02/26/2018 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2017 Results"
11/08/2017 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results"
08/09/2017 8-K Quarterly results
Docs: "Amended and Restated Credit Agreement, by and among the Registrant, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto",
"Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results"
05/08/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
08/09/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka achieves 71% total market share -- Bendeka leads with approximately 77% market share among hospital outpatients and clinics --"
11/12/2015 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Third Quarter 2015 Results"
08/11/2015 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Second Quarter 2015 Results"
05/12/2015 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports First Quarter 2015 Results"
05/14/2014 8-K Quarterly results
Docs: "Eagle Pharmaceuticals, Inc. Reports Second Quarter 2014 Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy